In Brief: Ephedrine
This article was originally published in The Tan Sheet
Executive Summary
Ephedrine: FDA accepting comments on its June 4 proposed rule establishing serving limits and label warnings for ephedrine-containing dietary supplements until Dec. 2. The agency announced in the Sept. 18 Federal Register the reopening of the comment period after rectifying "a number of inadvertent omissions from the administrative record." FDA also is providing the opportunity for comment on adverse event reports it has received between January and August and on "new analytical data" it is adding to the administrative record, including data on chemical analyses on several of the products associated with AE reports...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning